Orvepitant: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
== Orvepitant == | |||
Orvepitant | [[File:Orvepitant_structure.png|thumb|right|Chemical structure of Orvepitant]] | ||
'''Orvepitant''' is a [[neurokinin-1 receptor antagonist]] that has been investigated for its potential therapeutic effects in various conditions, including [[chronic cough]], [[depression]], and [[post-traumatic stress disorder]] (PTSD). It is a small molecule drug that works by blocking the action of [[substance P]], a neuropeptide involved in the transmission of pain and other sensory signals. | |||
== Mechanism of Action == | == Mechanism of Action == | ||
Orvepitant | Orvepitant functions as an antagonist at the [[neurokinin-1 receptor]] (NK1R), which is a receptor for [[substance P]]. By inhibiting the binding of substance P to NK1R, orvepitant can modulate the [[central nervous system]]'s response to stress and pain. This mechanism is thought to underlie its potential therapeutic effects in conditions like [[depression]] and [[anxiety disorders]]. | ||
== Clinical Applications == | |||
=== Chronic Cough === | |||
Orvepitant has been studied for its efficacy in treating [[chronic cough]], a condition characterized by a persistent cough lasting more than eight weeks. The drug's ability to block substance P is believed to reduce the cough reflex, providing relief to patients. | |||
=== Depression === | |||
In the context of [[depression]], orvepitant's role as a neurokinin-1 receptor antagonist may help alleviate symptoms by modulating the [[neurotransmitter]] systems involved in mood regulation. Studies have explored its use as an adjunctive treatment to enhance the effects of traditional [[antidepressants]]. | |||
By | === Post-Traumatic Stress Disorder === | ||
Orvepitant has also been investigated for its potential benefits in treating [[post-traumatic stress disorder]] (PTSD). By dampening the stress response mediated by substance P, orvepitant may help reduce the severity of PTSD symptoms. | |||
== | == Pharmacokinetics == | ||
Orvepitant is | Orvepitant is administered orally and undergoes [[hepatic metabolism]]. Its pharmacokinetic profile includes a moderate half-life, allowing for once-daily dosing in clinical settings. The drug is primarily excreted via the [[renal]] and [[biliary]] systems. | ||
== | == Safety and Tolerability == | ||
In clinical trials, orvepitant has been generally well-tolerated. Common side effects include [[nausea]], [[dizziness]], and [[headache]]. Serious adverse effects are rare but may include [[allergic reactions]] and [[liver enzyme]] elevations. | |||
== | == Research and Development == | ||
* [[Neurokinin 1 receptor | Orvepitant is still under investigation, with ongoing studies aimed at better understanding its efficacy and safety profile across different patient populations. Its development reflects a broader interest in targeting the neurokinin-1 receptor for various [[neuropsychiatric disorders]]. | ||
== Related Pages == | |||
* [[Neurokinin-1 receptor antagonist]] | |||
* [[Substance P]] | * [[Substance P]] | ||
* [[ | * [[Chronic cough]] | ||
* [[ | * [[Depression]] | ||
* [[Post-traumatic stress disorder]] | * [[Post-traumatic stress disorder]] | ||
[[Category: | [[Category:Pharmacology]] | ||
[[Category: | [[Category:Neurokinin-1 receptor antagonists]] | ||
Latest revision as of 11:16, 15 February 2025
Orvepitant[edit]
Orvepitant is a neurokinin-1 receptor antagonist that has been investigated for its potential therapeutic effects in various conditions, including chronic cough, depression, and post-traumatic stress disorder (PTSD). It is a small molecule drug that works by blocking the action of substance P, a neuropeptide involved in the transmission of pain and other sensory signals.
Mechanism of Action[edit]
Orvepitant functions as an antagonist at the neurokinin-1 receptor (NK1R), which is a receptor for substance P. By inhibiting the binding of substance P to NK1R, orvepitant can modulate the central nervous system's response to stress and pain. This mechanism is thought to underlie its potential therapeutic effects in conditions like depression and anxiety disorders.
Clinical Applications[edit]
Chronic Cough[edit]
Orvepitant has been studied for its efficacy in treating chronic cough, a condition characterized by a persistent cough lasting more than eight weeks. The drug's ability to block substance P is believed to reduce the cough reflex, providing relief to patients.
Depression[edit]
In the context of depression, orvepitant's role as a neurokinin-1 receptor antagonist may help alleviate symptoms by modulating the neurotransmitter systems involved in mood regulation. Studies have explored its use as an adjunctive treatment to enhance the effects of traditional antidepressants.
Post-Traumatic Stress Disorder[edit]
Orvepitant has also been investigated for its potential benefits in treating post-traumatic stress disorder (PTSD). By dampening the stress response mediated by substance P, orvepitant may help reduce the severity of PTSD symptoms.
Pharmacokinetics[edit]
Orvepitant is administered orally and undergoes hepatic metabolism. Its pharmacokinetic profile includes a moderate half-life, allowing for once-daily dosing in clinical settings. The drug is primarily excreted via the renal and biliary systems.
Safety and Tolerability[edit]
In clinical trials, orvepitant has been generally well-tolerated. Common side effects include nausea, dizziness, and headache. Serious adverse effects are rare but may include allergic reactions and liver enzyme elevations.
Research and Development[edit]
Orvepitant is still under investigation, with ongoing studies aimed at better understanding its efficacy and safety profile across different patient populations. Its development reflects a broader interest in targeting the neurokinin-1 receptor for various neuropsychiatric disorders.
